Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Smith & Nephew Plc
  6. News
  7. Summary
    SN.   GB0009223206

SMITH & NEPHEW PLC

(SN.)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Smith+Nephew Announces Study Results Showing Patients Treated with Just its REGENETEN Bioinductive Implant for Partial-Thickness Rotator Cuff Tears

07/21/2021 | 08:00am EDT

Smith+Nephew announced study results showing patients treated with just its REGENETEN Bioinductive Implant for partial-thickness rotator cuff tears (>3mm) experienced significantly improved shoulder function during early recovery compared to patients receiving a REGENETEN Implant plus traditional surgical repair, with equivalent efficacy at one year. Presented at the AOSSM-AANA Combined 2021 Annual Meeting, study investigators compared the use of a REGENETEN Implant alone (without surgical repair) to a REGENETEN Implant plus traditional surgical repair for the treatment of partial-thickness rotator cuff tears in 227 patients across 19 US surgical centers. Key findings of the study included: Compared with traditional surgical repair, patients reported a significant improvement in shoulder function in the early post-operative period (weeks 2 and 6) with the REGENETEN Implant alone; Treatment with the REGENETEN Implant alone demonstrated equivalent efficacy to REGENETEN plus traditional surgical repair with minimal revisions across both treatment groups at 1 year; Among all patients receiving a REGENETEN Implant, patients reported significant improvements in pain, function and quality of life from at 1 year compared with pre-surgery values.


ę S&P Capital IQ 2021
All news about SMITH & NEPHEW PLC
09/16European ADRs Move Lower in Thursday Trading
MT
09/16SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exc..
PU
09/15SMITH & NEPHEW : +Nephew commits to net zero emissions
PU
09/14SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exc..
PU
09/13SMITH & NEPHEW : TPG-backed Evercare eyes expansion of ex-Abraaj healthcare busi..
RE
09/10SMITH & NEPHEW : Barclays Reiterates Smith & Nephew At Overweight, Lowers PT
MT
09/02SMITH & NEPHEW : +Nephew introduces pioneering new technologies for its JOURNEY?..
AQ
09/02SMITH & NEPHEW : +Nephew to expand Real Intelligence digital ecosystem and CORI?..
AQ
09/01SMITH & NEPHEW : +Nephew introduces pioneering new technologies for its JOURNEY&..
PU
09/01SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exc..
PU
More news
Analyst Recommendations on SMITH & NEPHEW PLC
More recommendations
Financials (USD)
Sales 2021 5 381 M - -
Net income 2021 474 M - -
Net Debt 2021 1 936 M - -
P/E ratio 2021 34,3x
Yield 2021 1,93%
Capitalization 16 025 M 16 043 M -
EV / Sales 2021 3,34x
EV / Sales 2022 3,06x
Nbr of Employees 18 000
Free-Float 99,1%
Chart SMITH & NEPHEW PLC
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 18,25 $
Average target price 22,78 $
Spread / Average Target 24,8%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Roberto Quarta Chairman
Vasant Padmanabhan President-Research & Development
Catheryn O'Rourke Chief Legal & Compliance Officer
Sector and Competitors